Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers

Giulia Bon, Rossella Loria, Carla Azzurra Amoreo, Alessandra Verdina, Isabella Sperduti, Arianna Mastrofrancesco, Silvia Soddu, Maria Grazia Diodoro, Marcella Mottolese, Matilde Todaro, Giorgio Stassi, Michele Milella, Ruggero De Maria, Rita Falcioni

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Although the medical treatment of colorectal cancer has evolved greatly in the last years, a significant portion of early-stage patients develops recurrence after therapies. The current clinical trials are directed to evaluate new drug combinations and treatment schedules. By the use of patient-derived or established colon cancer cell lines, we found that the tyrosine kinase receptor HER3 is involved in the mechanisms of resistance to therapies. In agreement, the immunohistochemical analysis of total and phospho- HER3 expression in 185 colorectal cancer specimens revealed a significant correlation with lower disease-free survival. Targeting HER3 by the use of the monoclonal antibody patritumab we found induction of growth arrest in all cell lines. Despite the high efficiency of patritumab in abrogating the HER3-dependent activation of PI3K pathway, the HER2 and EGFRdependent MAPK pathway is activated as a compensatory mechanism. Interestingly, we found that the MEK-inhibitor trametinib inhibits, as expected, the MAPK pathway but induces the HER3-dependent activation of PI3K pathway. The combined treatment results in the abrogation of both PI3K and MAPK pathways and in a significant reduction of cell proliferation and survival. These data suggest a new strategy of therapy for HER3-overexpressing colon cancers.

Original languageEnglish
Pages (from-to)108463-108479
Number of pages17
JournalOncotarget
Volume8
Issue number65
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Mitogen-Activated Protein Kinase Kinases
Drug Resistance
Colonic Neoplasms
Phosphatidylinositol 3-Kinases
Colorectal Neoplasms
Therapeutics
Cell Line
Receptor Protein-Tyrosine Kinases
Drug Combinations
Disease-Free Survival
Cell Survival
Appointments and Schedules
Monoclonal Antibodies
Cell Proliferation
Clinical Trials
Recurrence
Growth

Keywords

  • Colon cancers
  • Drug resistance
  • HER3
  • MAPK
  • PI3K

ASJC Scopus subject areas

  • Oncology

Cite this

Bon, G., Loria, R., Amoreo, C. A., Verdina, A., Sperduti, I., Mastrofrancesco, A., ... Falcioni, R. (2017). Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers. Oncotarget, 8(65), 108463-108479. https://doi.org/10.18632/oncotarget.11400

Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers. / Bon, Giulia; Loria, Rossella; Amoreo, Carla Azzurra; Verdina, Alessandra; Sperduti, Isabella; Mastrofrancesco, Arianna; Soddu, Silvia; Diodoro, Maria Grazia; Mottolese, Marcella; Todaro, Matilde; Stassi, Giorgio; Milella, Michele; De Maria, Ruggero; Falcioni, Rita.

In: Oncotarget, Vol. 8, No. 65, 01.01.2017, p. 108463-108479.

Research output: Contribution to journalArticle

Bon, G, Loria, R, Amoreo, CA, Verdina, A, Sperduti, I, Mastrofrancesco, A, Soddu, S, Diodoro, MG, Mottolese, M, Todaro, M, Stassi, G, Milella, M, De Maria, R & Falcioni, R 2017, 'Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers', Oncotarget, vol. 8, no. 65, pp. 108463-108479. https://doi.org/10.18632/oncotarget.11400
Bon, Giulia ; Loria, Rossella ; Amoreo, Carla Azzurra ; Verdina, Alessandra ; Sperduti, Isabella ; Mastrofrancesco, Arianna ; Soddu, Silvia ; Diodoro, Maria Grazia ; Mottolese, Marcella ; Todaro, Matilde ; Stassi, Giorgio ; Milella, Michele ; De Maria, Ruggero ; Falcioni, Rita. / Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers. In: Oncotarget. 2017 ; Vol. 8, No. 65. pp. 108463-108479.
@article{425746bf8d45457ebdd6960939941268,
title = "Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers",
abstract = "Although the medical treatment of colorectal cancer has evolved greatly in the last years, a significant portion of early-stage patients develops recurrence after therapies. The current clinical trials are directed to evaluate new drug combinations and treatment schedules. By the use of patient-derived or established colon cancer cell lines, we found that the tyrosine kinase receptor HER3 is involved in the mechanisms of resistance to therapies. In agreement, the immunohistochemical analysis of total and phospho- HER3 expression in 185 colorectal cancer specimens revealed a significant correlation with lower disease-free survival. Targeting HER3 by the use of the monoclonal antibody patritumab we found induction of growth arrest in all cell lines. Despite the high efficiency of patritumab in abrogating the HER3-dependent activation of PI3K pathway, the HER2 and EGFRdependent MAPK pathway is activated as a compensatory mechanism. Interestingly, we found that the MEK-inhibitor trametinib inhibits, as expected, the MAPK pathway but induces the HER3-dependent activation of PI3K pathway. The combined treatment results in the abrogation of both PI3K and MAPK pathways and in a significant reduction of cell proliferation and survival. These data suggest a new strategy of therapy for HER3-overexpressing colon cancers.",
keywords = "Colon cancers, Drug resistance, HER3, MAPK, PI3K",
author = "Giulia Bon and Rossella Loria and Amoreo, {Carla Azzurra} and Alessandra Verdina and Isabella Sperduti and Arianna Mastrofrancesco and Silvia Soddu and Diodoro, {Maria Grazia} and Marcella Mottolese and Matilde Todaro and Giorgio Stassi and Michele Milella and {De Maria}, Ruggero and Rita Falcioni",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.11400",
language = "English",
volume = "8",
pages = "108463--108479",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "65",

}

TY - JOUR

T1 - Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers

AU - Bon, Giulia

AU - Loria, Rossella

AU - Amoreo, Carla Azzurra

AU - Verdina, Alessandra

AU - Sperduti, Isabella

AU - Mastrofrancesco, Arianna

AU - Soddu, Silvia

AU - Diodoro, Maria Grazia

AU - Mottolese, Marcella

AU - Todaro, Matilde

AU - Stassi, Giorgio

AU - Milella, Michele

AU - De Maria, Ruggero

AU - Falcioni, Rita

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Although the medical treatment of colorectal cancer has evolved greatly in the last years, a significant portion of early-stage patients develops recurrence after therapies. The current clinical trials are directed to evaluate new drug combinations and treatment schedules. By the use of patient-derived or established colon cancer cell lines, we found that the tyrosine kinase receptor HER3 is involved in the mechanisms of resistance to therapies. In agreement, the immunohistochemical analysis of total and phospho- HER3 expression in 185 colorectal cancer specimens revealed a significant correlation with lower disease-free survival. Targeting HER3 by the use of the monoclonal antibody patritumab we found induction of growth arrest in all cell lines. Despite the high efficiency of patritumab in abrogating the HER3-dependent activation of PI3K pathway, the HER2 and EGFRdependent MAPK pathway is activated as a compensatory mechanism. Interestingly, we found that the MEK-inhibitor trametinib inhibits, as expected, the MAPK pathway but induces the HER3-dependent activation of PI3K pathway. The combined treatment results in the abrogation of both PI3K and MAPK pathways and in a significant reduction of cell proliferation and survival. These data suggest a new strategy of therapy for HER3-overexpressing colon cancers.

AB - Although the medical treatment of colorectal cancer has evolved greatly in the last years, a significant portion of early-stage patients develops recurrence after therapies. The current clinical trials are directed to evaluate new drug combinations and treatment schedules. By the use of patient-derived or established colon cancer cell lines, we found that the tyrosine kinase receptor HER3 is involved in the mechanisms of resistance to therapies. In agreement, the immunohistochemical analysis of total and phospho- HER3 expression in 185 colorectal cancer specimens revealed a significant correlation with lower disease-free survival. Targeting HER3 by the use of the monoclonal antibody patritumab we found induction of growth arrest in all cell lines. Despite the high efficiency of patritumab in abrogating the HER3-dependent activation of PI3K pathway, the HER2 and EGFRdependent MAPK pathway is activated as a compensatory mechanism. Interestingly, we found that the MEK-inhibitor trametinib inhibits, as expected, the MAPK pathway but induces the HER3-dependent activation of PI3K pathway. The combined treatment results in the abrogation of both PI3K and MAPK pathways and in a significant reduction of cell proliferation and survival. These data suggest a new strategy of therapy for HER3-overexpressing colon cancers.

KW - Colon cancers

KW - Drug resistance

KW - HER3

KW - MAPK

KW - PI3K

UR - http://www.scopus.com/inward/record.url?scp=85037676886&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85037676886&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.11400

DO - 10.18632/oncotarget.11400

M3 - Article

VL - 8

SP - 108463

EP - 108479

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 65

ER -